2005
Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma
Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma. Cancer 2005, 104: 682-691. PMID: 15986399, DOI: 10.1002/cncr.21227.Peer-Reviewed Original ResearchConceptsAdministration of tariquidarP-gp expressionSestamibi scanBreast carcinomaSestamibi uptakeP-gp-positive tumorsTaxane-containing chemotherapy regimensDocetaxel-related toxicitiesLimited clinical activityObjective tumor responsePercent of patientsPhase II studyAdvanced breast carcinomaP-glycoprotein inhibitor tariquidarP-glycoprotein inhibitorsMultidrug resistance modulationP-gp transporterMultidrug resistance inhibitorsSame chemotherapyStable diseaseChemotherapy regimenChemotherapy regimensTaxane chemotherapyClinical responseDose modification
2001
Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Esteva F, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar A, Hortobagyi G. Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. The Oncologist 2001, 6: 133-146. PMID: 11306725, DOI: 10.1634/theoncologist.6-2-133.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHER-2/neu proteinAnthracycline/taxane combinationsDevelopment of anthracyclineAdvanced breast cancerHigh-dose chemotherapyPrimary breast cancerSingle-agent activityCombination chemotherapy treatmentsNovel biologic therapiesNovel treatment approachesMultidrug resistance inhibitorsTopoisomerase I inhibitorTaxane therapyBiologic therapyPalliative therapyTaxane combinationsProlong survivalTumor supressor geneChemotherapy treatmentTreatment approachesFluoropyrimidine analogsPatientsNeu protein